HIV/AIDS
| Development of medicine for treating HIV infections | Over time, Shionogi and ViiV Healthcare have engaged in the joint research and development of dolutegravir, a new HIV integrase inhibitor. Developing countries account for more than 40% of the total global supply volume of the anti-HIV agent Tivicay® (dolutegravir), which is licensed to ViiV Healthcare , and its combinant drugs Triumeq® and Juluca®.
Starting in December 2012, ViiV Healthcare submitted New Drug Applications (NDAs) in the United States, Europe, Japan and other regions to have As of today, the drug has been made available for sale globally under the product name "Tivicay®. Registering dolutegravir in the Medicines Patent Pool has allowed generic manufacturers to manufacturer dolutegravir, either as a single-ingredient Registering dolutegravir in the Medicines Patent Pool has allowed generic manufacturers to manufacturer dolutegravir, either as a single-ingredient formulation or combined with other anti-HIV agents, and distribute it to more than 130 low-income and lower-middle-income countries since the patent is available free of charge. |
|---|